Key clinical point: Pioglitazone was associated with a significant reduction in Psoriasis Area and Severity Index (PASI) scores.
Major finding: The treatment success rate overall was significantly higher in patients treated with pioglitazone compared with controls (risk ratio 3.60); the weight mean difference was 2.68.
Study details: The data come from a meta-analysis of 6 randomized, controlled trials including 270 individuals with psoriasis vulgaris.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Chen P et al. Medicine. 2020 Aug 7. doi: 10.1097/MD. 0000000000021549.